B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.

Autor: Lovett-Racke AE; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: amy.lovett-racke@osumc.edu., Yang Y; Department of Neurology, The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Liu Y; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Gormley M; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Kraus E; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Graham C; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Wray S; Hope Neurology Multiple Sclerosis Center, Knoxville, TN, USA., Racke MK; Department of Neurology, The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Alvarez E; Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA., Bass A; Neurology Center of San Antonio, San Antonio, TX, USA., Fox E; Central Texas Neurology Consultants, UT Dell Medical School, Austin, TX, USA.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2021 Oct 15; Vol. 359, pp. 577676. Date of Electronic Publication: 2021 Jul 30.
DOI: 10.1016/j.jneuroim.2021.577676
Abstrakt: B cell depletion therapy has been shown to be beneficial in multiple sclerosis (MS). However, the mechanism by which B cell depletion mediates its beneficial effects in MS is still unclear. To better understand how B cell depletion may benefit patients with a disease previously thought to be primarily mediated by CD4 T cells, immune profiles were monitored in 48 patients in a phase II trial of ublituximab, a glycoengineered CD20 monoclonal antibody, at 18 time points over a year. As we previously described there was a significant shift in the percentages of T cells, NK cells, and myeloid cells following the initial dose of ublituximab, but this shift normalized within a week and these populations remained stable for the duration of the study. However, T cell subsets changed with an increase in the percentage of naïve CD4 and CD8 T cells and a decline in memory T cells. Importantly, the percentage of Th1 and CD4 + GM-CSF + T cells decreased, while the percentage of Tregs continued to increase over the year. Ublituximab not only depleted CD20 + B cells, but also CD20 + T cells. The favorable changes in the T cell subsets may contribute to the beneficial effects of B cell depletion therapy.
(Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: